Highlights
- •Tacrolimus therapy is associated with higher overall survial rate compared with conventional therapy in dermatomyositis and polymyositis patients.
- •Tacrolimus therapy could improve forced vital capacity in dermatomyositis and polymyositis patients with interstitial lung disease.
- •Tacrolimus therapy showed satisfactory safety profile in dermatomyositis and polymyositis patients.
Abstract
Objective
To evaluate the efficacy and safety of tacrolimus for dermatomyositis (DM) and polymyositis
(PM) treatment.
Methods
We searched the Embase, PubMed, the Cochrane Central Register of Controlled Trials,
and China National Knowledge Infrastructure were used as searching tools from inception
up to October 2022. Two authors independently selected studies. The available studies
were comprehensively reviewed and investigated.
Results
A total of 9 studies, including 350 patients, were analysed. Pooled results showed
a higher overall survival rate in tacrolimus therapy group. Creatine kinase (CK) levels
and forced vital capacity (FVC) showed significant improvement after tacrolimus therapy.
The incidence of adverse events including infection and renal dysfunction showed no
significant differences between the tacrolimus therapy group and conventional therapy
group.
Conclusion
The results of this meta-analysis indicated that GC therapy in combination with tacrolimus
therapy could help improving overall survival rate, pulmonary function and had similar
safety outcomes compared to conventional therapy in DM and PM patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine.Arthritis Res Ther. 2012; 14: R22https://doi.org/10.1186/ar3704
- Prognosis and mortality of polymyositis and dermatomyositis patients.Clin Rheumatol. 2006; 25: 234-239https://doi.org/10.1007/s10067-005-1164-z
- AB0627 prognosis and mortality of dermatomyositis and polymyositis patients with malignancy.Ann Rheum Dis. 2020; 79 (Suppl): 1609https://doi.org/10.1136/annrheumdis-2020-eular.4048
- Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease.Lung. 2016; 194: 733-737https://doi.org/10.1007/s00408-016-9896-x
- British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy.Rheumatology. 2022; 61 (Oxford) (Oxford, England): 1760-1768https://doi.org/10.1093/rheumatology/keac115
- Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.Arthritis Rheumatol. 2005; 52: 2439-2446https://doi.org/10.1002/art.21240
- Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: a randomized, open-label trial.Respirology. 2020; https://doi.org/10.1111/resp.13978
- Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists.Mod Rheumatol. 2019; 29: 1-19https://doi.org/10.1080/14397595.2018.1521185
- Polymyositis and dermatomyositis (first of two parts).N Engl J Med. 1975; 292: 344-347https://doi.org/10.1056/nejm197502132920706
- 2017 European league against rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.Ann Rheum Dis. 2017; 76: 1955-1964https://doi.org/10.1136/annrheumdis-2017-211468
- Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects.Dermatol Clin. 2002; 20: 387-408https://doi.org/10.1016/s0733-8635(02)00021-9
- Tacrolimus in patients with interstitial pneumonia associated with polymyositis or dermatomyositis: interim report of postmarketing surveillance in Japan.J Rheumatol. 2022; 49: 707-718https://doi.org/10.3899/jrheum.210322
- Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti–melanoma differentiation–associated Gene 5–positive dermatomyositis.Arthritis Rheumatol. 2020; 72 (Hoboken, N.J.): 488-498https://doi.org/10.1002/art.41105
- Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial.Rheumatology. 2020; 59 (Oxford): 1084-1093https://doi.org/10.1093/rheumatology/kez394
- Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis.Mod Rheumatol. 2015; 25: 888-892https://doi.org/10.3109/14397595.2015.1029239
- Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature.Clin Rheumatol. 2012; 31: 1493-1498https://doi.org/10.1007/s10067-012-2044-y
- Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis.Int J Rheum Dis. 2016; 19: 1322-1330https://doi.org/10.1111/1756-185X.12931
- The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis.Rheumatology. 2014; 54 (United Kingdom): 39-44https://doi.org/10.1093/rheumatology/keu166
- Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies.Adv Rheumatol. 2019; 59: 6https://doi.org/10.1186/s42358-019-0048-x
- Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis.Clin Exp Immunol. 2002; 129: 541-548https://doi.org/10.1046/j.1365-2249.2002.01933.x
- The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review.Clin Rheumatol. 2015; 34: 2097-2103https://doi.org/10.1007/s10067-015-3065-0
Article info
Publication history
Published online: January 30, 2023
Accepted:
January 23,
2023
Received in revised form:
January 14,
2023
Received:
December 4,
2022
Identification
Copyright
© 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
